Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

Summary

This phase II trial studies the side effects of pembrolizumab and to see how well it works in treating patients with bladder cancer who are undergoing surgery to remove the bladder. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2018-01-11

Primary completion

2023-05-01

Completion

2023-05-01

Drugs

Indications